• This record comes from PubMed

Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial

. 2016 Apr 26 ; 133 (17) : 1637-44. [epub] 20160330

Language English Country United States Media print-electronic

Document type Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial

BACKGROUND: Whether catheter ablation (CA) is superior to amiodarone (AMIO) for the treatment of persistent atrial fibrillation (AF) in patients with heart failure is unknown. METHODS AND RESULTS: This was an open-label, randomized, parallel-group, multicenter study. Patients with persistent AF, dual-chamber implantable cardioverter defibrillator or cardiac resynchronization therapy defibrillator, New York Heart Association II to III, and left ventricular ejection fraction <40% within the past 6 months were randomly assigned (1:1 ratio) to undergo CA for AF (group 1, n=102) or receive AMIO (group 2, n=101). Recurrence of AF was the primary end point. All-cause mortality and unplanned hospitalization were the secondary end points. Patients were followed up for a minimum of 24 months. At the end of follow-up, 71 (70%; 95% confidence interval, 60%-78%) patients in group 1 were recurrence free after an average of 1.4±0.6 procedures in comparison with 34 (34%; 95% confidence interval, 25%-44%) in group 2 (log-rank P<0.001). The success rate of CA in the different centers after a single procedure ranged from 29% to 61%. After adjusting for covariates in the multivariable model, AMIO therapy was found to be significantly more likely to fail (hazard ratio, 2.5; 95% confidence interval, 1.5-4.3; P<0.001) than CA. Over the 2-year follow-up, the unplanned hospitalization rate was (32 [31%] in group 1 and 58 [57%] in group 2; P<0.001), showing 45% relative risk reduction (relative risk, 0.55; 95% confidence interval, 0.39-0.76). A significantly lower mortality was observed in CA (8 [8%] versus AMIO (18 [18%]; P=0.037). CONCLUSIONS: This multicenter randomized study shows that CA of AF is superior to AMIO in achieving freedom from AF at long-term follow-up and reducing unplanned hospitalization and mortality in patients with heart failure and persistent AF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00729911.

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

Comment In

PubMed

References provided by Crossref.org

Newest 20 citations...

See more in
Medvik | PubMed

Atrial Fibrillation Ablation During Hospitalization for Acute Heart Failure: Feasibility and Role of Pulsed Field Ablation

. 2025 Jan ; 36 (1) : 256-265. [epub] 20241126

Catheter ablation for non-paroxysmal atrial fibrillation. A review

. 2024 Mar ; 168 (1) : 1-14. [epub] 20240115

Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation

. 2019 Dec 07 ; 40 (46) : 3793-3799c.

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary

. 2018 Jan 01 ; 20 (1) : 157-208.

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

. 2018 Jan 01 ; 20 (1) : e1-e160.

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

. 2017 Oct ; 14 (10) : e275-e444. [epub] 20170512

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary

. 2017 Oct ; 33 (5) : 369-409. [epub] 20170915

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary

. 2017 Oct ; 50 (1) : 1-55.

See more in PubMed

ClinicalTrials.gov
NCT00729911

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...